Ono Pharmaceutical Closes Deciphera Deal for About $2.4 Billion
Provided by
Dow Jones
By Josh Beckerman
Ono Pharmaceutical completed its purchase of Deciphera Pharmaceuticals for about $2.4 billion.
Nasdaq halted Deciphera shares late Monday, seeking additional information. Ono said Tuesday that it successfully completed a $25.60-a-share tender offer for the cancer-focused biopharmaceutical company. The deal was announced in April.
Deciphera reported a fourth-quarter loss of 54 cents a share on total revenue of $48.3 million in February.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
June 11, 2024 13:24 ET (17:24 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks
-
Real Estate: Performance Continues to Be Driven by Interest-Rate Movements
-
Financial Services: Sector Doing Well Heading Into Rate-Cutting Cycle
-
Energy: OPEC Faces Hard Supply Decision in Latter Half of 2024
-
This Cheap Stock Is Still a Buy Even After 50% Rally
United States